<trans-title xml:lang="en"/>_West China Medical Journal

Authors：

 戢艷麗 , 梅小麗 , 楊梅 , 鄭希 , 趙雍凡

四川大學華西醫院胸外科（成都 610041）;

Corresponding?author：

戢艷麗, Email: baxia_-jyl@qq.com

Keywords：

食管癌; 淋巴結; 轉移; 治療進展

DOI：

10.7507/1002-0179.201511026

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

淋巴結是食管癌轉移的主要部位，其淋巴引流區域涉及頸部、胸部和腹部，對其進行有效的檢測，對客觀、準確評價病情，指導臨床選擇個體化、多模式的治療方式，改善食管癌患者的預后至關重要。文章旨在多方位、多角度探討食管癌轉移淋巴結的治療理念和模式，歸納、總結近年來針對食管癌轉移淋巴結的治療相關的研究進展。

Citation： 戢艷麗, 梅小麗, 楊梅, 鄭希, 趙雍凡. . West China Medical Journal, 2017, 32(1): 137-142. doi: 10.7507/1002-0179.201511026 Copy

1.	Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin, 2013, 63(4): 232-248.
2.	Higuchi K, Koizumi W, Tanabe S,et al. Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res, 2009, 3(4): 153-161.
3.	Zhang HZ, Jin GF, Shen HB. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer, 2012, 31(6): 281-286.
4.	Chinese Center for Disease Control and Prevention. National disease surveillance system monitoring causes of death 2010. Beijing: Military Medical Science Press, 2012.
5.	International Agency For Research On Cancer. Globocan 2012: estimated incidence, mortality and prevalence worldwide in 2012. Lyon: International Agency For Research On Cancer, 2012.
6.	Kayani B, Zacharakis E, Ahmed K,et al. Lymph node metastases and prognosis in oesophageal carcinoma--a systematic review. Eur J Surg Oncol, 2011, 37(9): 747-753.
7.	Zhang HL, Chen LQ, Liu RL,et al. The number of lymph node metastases influences survival and International Union Against Cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma. Dis Esophagus, 2010, 23(1): 53-58.
8.	Kawahara K, Maekawa T, Okabayashi K,et al. The number of lymph node metastases influences survival in esophageal cancer. J Surg Oncol, 1998, 67(3): 160-163.
9.	Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol, 2010, 17(7): 1721-1724.
10.	Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471-1474.
11.	Nabeya K, Nakata Y. Extent of resection and lymphadenectomy in early squamous cell esophageal cancer. Dis Esophagus, 1997, 10(3): 159-161.
12.	Leers JM, Demeester SR, Oezcelik A,et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg, 2011, 253(2): 271-278.
13.	Rice TW. Superficial oesophageal carcinoma: is there a need for three-field lymphadenectomy?. Lancet, 1999, 354(9181): 792-794.
14.	Kuge K, Murakami G, Mizobuchi S,et al. Submucosal territory of the direct lymphatic drainage system to the thoracic duct in the human esophagus. J Thorac Cardiovasc Surg, 2003, 125(6): 1343-1349.
15.	Tachimori Y, Nagai Y, Kanamori N,et al. Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system. Dis Esophagus, 2011, 24(1): 33-38.
16.	Riquet M, Saab M, Le Pimpec Barthes F,et al. Lymphatic drainage of the esophagus in the adult. Surg Radiol Anat, 1993, 15(3): 209-211.
17.	Rice TW, Zuccaro G, Adelstein DJ,et al. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg, 1998, 65(3): 787-792.
18.	Crehange G, Bonnetain F, Peignaux K,et al. Preoperative radiochemotherapy for resectable localised oesophageal cancer: a controversial strategy. Crit Rev Oncol Hematol, 2010, 75(3): 235-242.
19.	Kelsen DP, Ginsberg R, Pajak TF,et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med, 1998, 339(27): 1979-1984.
20.	Ychou M, Boige V, Pignon JP,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial. J Clin Oncol, 2011, 29(13): 1715-1721.
21.	Sjoquist KM, Burmeister BH, Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol, 2011, 12(7): 681-692.
22.	Allum WH, Stenning SP, Bancewicz J,et al. Long-Term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 2009, 27(30): 5062-5067.
23.	Ando N, Kato H, Igaki H,et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracilversus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol, 2012, 19(1): 68-74.
24.	Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol, 2010, 16(30): 3793-3803.
25.	Gebski V, Burmeister B, Smithers BM,et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol, 2007, 8(3): 226-234.
26.	Arnott SJ, Duncan W, Gignoux M,et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev, 2000(4): CD001799.
27.	Wolf MC, Stahl M, Krause BJ,et al. Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol, 2011, 6(6): 55.
28.	Urba SG, Orringer MB, Turrisi A,et al. Randomized trial of preoperative chemoradiationversus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol, 2001, 19(2): 305-313.
29.	van Hagen P, Hulshof M, van Lanschot J,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012, 366(22): 2074-2084.
30.	Zacherl J. The current evidence in support of multimodal treatment of locally advanced, potentially resectable esophageal cancer. Dig Dis, 2014, 32(1/2): 171-175.
31.	Bosset JF, Gignoux M, Triboulet JP,et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med, 1997, 337(3): 161-167.
32.	Lv J, Cao XF, Zhu B,et al. Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol, 2009, 15(39): 4962-4968.
33.	Liao ZX, Cox JD, Komaki R. Radiochemotherapy of esophageal cancer. J Thorac Oncol, 2007, 2(6): 553-568.
34.	Castoro C, Scarpa M, Cagol M,et al. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution. Ann Surg Oncol, 2011, 18(13): 3743-3754.
35.	Stahl M, Walz MK, Stuschke M,et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol, 2009, 27(6): 851-856.
36.	Altorki NK, Zhou XK, Stiles B,et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg, 2008, 248(2): 221-226.
37.	Altorki NK. Three-field lymphadenectomy for esophageal cancer. Chest Surg Clin N A, 2000, 10(3): 553-560.
38.	Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg, 1998, 175(1): 47-51.
39.	Altorki NK, Skinner DB. Occult cervical nodal metastasis in esophageal cancer: preliminary results of three-field lymphadenectomy. J Thorac Cardiovasc Surg, 1997, 113(3): 540-544.
40.	Lerut T, Nafteux P, Moons J,et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R₀ resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg, 2004, 240(6): 962-972; discussion 972-974.
41.	方文濤, 陳文虎, 陳勇, 等. 選擇性頸胸腹三野淋巴結清掃治療胸段食管鱗癌. 中華胃腸外科雜志, 2006, 9(5): 388-391.
42.	Mariette C, Balon JM, Piessen G,et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer, 2003, 97(7): 1616-1623.
43.	Tachibana M, Kinugasa S, Yoshimura H,et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg, 2005, 189(1): 98-109.
44.	Law S, Wong J. Two-field dissection is enough for esophageal cancer. Dis Esophagus, 2001, 14(2): 98-103.
45.	Nakamura T, Ota M, Narumiya K,et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol, 2008, 15(9): 2451-2457.
46.	Pennathur A, Zhang J, Chen H,et al. The “Best Operation” for Esophageal Cancer?. Ann Thorac Surg, 2010, 89(6): S2163-S2167.
47.	Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol, 2007, 8(6): 545-553.
48.	Ando N, Iizuka T, Ide H,et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study——JCOG9204. J Clin Oncol, 2003, 21(24): 4592-4596.
49.	Pouliquen X, Levard H, Hay JM,et al. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg, 1996, 223(2): 127-133.
50.	Nagawa H, Seto Y, Kobori O,et al. An experience of treatment for patients with thoracic esophageal cancer invading adjacent organs. Jpn J Clin Oncol, 1997, 27(4): 248-250.
51.	Armanios M, Xu R, Forastiere AA,et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase Ⅱ trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol, 2004, 22(22): 4495-4499.
52.	Ténière P, Hay JM, Fingerhut A,et al. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet, 1991, 173(2): 123-130.
53.	Zieren HU, Müller JM, Jacobi CA,et al. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg, 1995, 19(3): 444-449.
54.	Fok M, Sham JS, Choy D,et al. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery, 1993, 113(2): 138-147.
55.	Xiao ZF, Yang ZY, Liang J,et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg, 2003, 75(2): 331-336.
56.	Malthaner RA, Wong RK, Rumble RB,et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med, 2004, 2(1): 35.
57.	Almhanna K, Shridhar R, Meredith KL. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?. Cancer Control, 2013, 20(2): 89-96.
58.	Bédard EL, Inculet RI, Malthaner RA,et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer, 2001, 91(12): 2423-2430.
59.	Adelstein DJ, Rice TW, Rybicki LA,et al. Mature results from a phase Ⅱ trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol, 2009, 4(10): 1264-1269.
60.	Chen JQ, Pan JJ, Liu J,et al. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2013, 86(4): 671-677.
61.	Tachibana M, Yoshimura H, Kinugasa S,et al. Postoperative chemotherapyvs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol, 2003, 29(7): 580-587.
62.	Ma DY, Tan BX, Liu M,et al. Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study. Radiat Oncol, 2014, 9(9): 28.
63.	Zhang J, Peng F, Li N,et al. Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer. Radiat Oncol, 2012, 7(7): 93.
64.	Bao Y, Liu S, Zhou Q,et al. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern. Radiat Oncol, 2013, 8(8): 241.
65.	Walsh TN, Noonan N, Hollywood D,et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med, 1996, 335(7): 462-467.
66.	Crosby TD, Brewster AE, Borley A,et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer, 2004, 90(1): 70-75.
67.	Ohtsu A, Boku N, Muro K,et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol, 1999, 17(8): 2915-2921.
68.	Ishikura S, Nihei K, Ohtsu A,et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol, 2003, 21(14): 2697-2702.
69.	Hironaka S, Ohtsu A, Boku N,et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys, 2003, 57(2): 425-433.
70.	Chiu PW, Chan AC, Leung SF,et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE) J Gastrointest Surg, 2005, 9(6): 794-802.
71.	Besharat S, Jabbari A, Semnani S,et al. Inoperable esophageal cancer and outcome of palliative care. World J Gastroenterol, 2008, 14(23): 3725-3728.
72.	Yano T, Muto M, Minashi K,et al. Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc, 2005, 62(1): 31-36.
73.	Lightdale CJ, Heier SK, Marcon NE,et al. Photodynamic therapy with porfimer sodiumversus thermal ablation therapy with Nd: YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc, 1995, 42(6): 507-512.
74.	Müller JM, Erasmi H, Stelzner M,et al. Surgical therapy for esophageal adenocarcinoma. J Gastrointest Surg, 2002, 6(4): 515.
75.	Frenken M. Best palliation in esophageal cancer: surgery, stenting, radiation, or what?. Dis Esophagus, 2001, 14(2): 120-123.
76.	Freeman RK, Ascioti AJ, Mahidhara RJ. Palliative therapy for patients with unresectable esophageal carcinoma. Surg Clin North Am, 2012, 92(5): 1337-1351.
77.	Mohamed A, El-Rayes B, Khuri FR,et al. Targeted therapies in metastatic esophageal cancer: advances over the past decade. Crit Rev Oncol Hematol, 2014, 91(2): 186-196.
78.	Hong TS, Wo JY, Kwak EL. Targeted therapies with chemoradiation in esophageal cancer: development and future directions. Semin Radiat Oncol, 2013, 23(1): 31-37.
79.	Lin CC, Papadopoulos KP. Novel targeted therapies for advanced esophageal cancer. Dis Esophagus, 2007, 20(5): 365-371.
80.	Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist, 2005, 10(8): 590-601.
81.	Tabernero J, Macarulla T, Ramos FJ,et al. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol, 2005, 16(11): 1740-1748.
82.	Liberman M, Hanna N, Duranceau A,et al. Endobronchial ultrasonography added to endoscopic ultrasonography improves staging in esophageal cancer. Ann Thorac Surg, 2013, 96(1): 232-236; discussion 236.
83.	van Vliet EP, Heijenbrok-Kal MH, Hunink MG,et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer, 2008, 98(3): 547-557.
84.	Meyers BF, Downey RJ, Decker PA,et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg, 2007, 133(3): 738-745.
85.	Luketich JD, Kassis ES, Shriver SP,et al. Detection of micrometastases in histologically negative lymph nodes in esophageal cancer. Ann Thorac Surg, 1998, 66(5): 1715-1718.
86.	Prenzel KL, H?lscher AH, Drebber U,et al. Prognostic impact of nodal micrometastasis in early esophageal cancer. Eur J Surg Oncol, 2012, 38(4): 314-318.

1. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin, 2013, 63(4): 232-248.
2. Higuchi K, Koizumi W, Tanabe S,et al. Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res, 2009, 3(4): 153-161.
3. Zhang HZ, Jin GF, Shen HB. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer, 2012, 31(6): 281-286.
4. Chinese Center for Disease Control and Prevention. National disease surveillance system monitoring causes of death 2010. Beijing: Military Medical Science Press, 2012.
5. International Agency For Research On Cancer. Globocan 2012: estimated incidence, mortality and prevalence worldwide in 2012. Lyon: International Agency For Research On Cancer, 2012.
6. Kayani B, Zacharakis E, Ahmed K,et al. Lymph node metastases and prognosis in oesophageal carcinoma--a systematic review. Eur J Surg Oncol, 2011, 37(9): 747-753.
7. Zhang HL, Chen LQ, Liu RL,et al. The number of lymph node metastases influences survival and International Union Against Cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma. Dis Esophagus, 2010, 23(1): 53-58.
8. Kawahara K, Maekawa T, Okabayashi K,et al. The number of lymph node metastases influences survival in esophageal cancer. J Surg Oncol, 1998, 67(3): 160-163.
9. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol, 2010, 17(7): 1721-1724.
10. Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471-1474.
11. Nabeya K, Nakata Y. Extent of resection and lymphadenectomy in early squamous cell esophageal cancer. Dis Esophagus, 1997, 10(3): 159-161.
12. Leers JM, Demeester SR, Oezcelik A,et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg, 2011, 253(2): 271-278.
13. Rice TW. Superficial oesophageal carcinoma: is there a need for three-field lymphadenectomy?. Lancet, 1999, 354(9181): 792-794.
14. Kuge K, Murakami G, Mizobuchi S,et al. Submucosal territory of the direct lymphatic drainage system to the thoracic duct in the human esophagus. J Thorac Cardiovasc Surg, 2003, 125(6): 1343-1349.
15. Tachimori Y, Nagai Y, Kanamori N,et al. Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system. Dis Esophagus, 2011, 24(1): 33-38.
16. Riquet M, Saab M, Le Pimpec Barthes F,et al. Lymphatic drainage of the esophagus in the adult. Surg Radiol Anat, 1993, 15(3): 209-211.
17. Rice TW, Zuccaro G, Adelstein DJ,et al. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg, 1998, 65(3): 787-792.
18. Crehange G, Bonnetain F, Peignaux K,et al. Preoperative radiochemotherapy for resectable localised oesophageal cancer: a controversial strategy. Crit Rev Oncol Hematol, 2010, 75(3): 235-242.
19. Kelsen DP, Ginsberg R, Pajak TF,et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med, 1998, 339(27): 1979-1984.
20. Ychou M, Boige V, Pignon JP,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial. J Clin Oncol, 2011, 29(13): 1715-1721.
21. Sjoquist KM, Burmeister BH, Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol, 2011, 12(7): 681-692.
22. Allum WH, Stenning SP, Bancewicz J,et al. Long-Term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 2009, 27(30): 5062-5067.
23. Ando N, Kato H, Igaki H,et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracilversus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol, 2012, 19(1): 68-74.
24. Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol, 2010, 16(30): 3793-3803.
25. Gebski V, Burmeister B, Smithers BM,et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol, 2007, 8(3): 226-234.
26. Arnott SJ, Duncan W, Gignoux M,et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev, 2000(4): CD001799.
27. Wolf MC, Stahl M, Krause BJ,et al. Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol, 2011, 6(6): 55.
28. Urba SG, Orringer MB, Turrisi A,et al. Randomized trial of preoperative chemoradiationversus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol, 2001, 19(2): 305-313.
29. van Hagen P, Hulshof M, van Lanschot J,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012, 366(22): 2074-2084.
30. Zacherl J. The current evidence in support of multimodal treatment of locally advanced, potentially resectable esophageal cancer. Dig Dis, 2014, 32(1/2): 171-175.
31. Bosset JF, Gignoux M, Triboulet JP,et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med, 1997, 337(3): 161-167.
32. Lv J, Cao XF, Zhu B,et al. Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol, 2009, 15(39): 4962-4968.
33. Liao ZX, Cox JD, Komaki R. Radiochemotherapy of esophageal cancer. J Thorac Oncol, 2007, 2(6): 553-568.
34. Castoro C, Scarpa M, Cagol M,et al. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution. Ann Surg Oncol, 2011, 18(13): 3743-3754.
35. Stahl M, Walz MK, Stuschke M,et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol, 2009, 27(6): 851-856.
36. Altorki NK, Zhou XK, Stiles B,et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg, 2008, 248(2): 221-226.
37. Altorki NK. Three-field lymphadenectomy for esophageal cancer. Chest Surg Clin N A, 2000, 10(3): 553-560.
38. Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg, 1998, 175(1): 47-51.
39. Altorki NK, Skinner DB. Occult cervical nodal metastasis in esophageal cancer: preliminary results of three-field lymphadenectomy. J Thorac Cardiovasc Surg, 1997, 113(3): 540-544.
40. Lerut T, Nafteux P, Moons J,et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R₀ resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg, 2004, 240(6): 962-972; discussion 972-974.
41. 方文濤, 陳文虎, 陳勇, 等. 選擇性頸胸腹三野淋巴結清掃治療胸段食管鱗癌. 中華胃腸外科雜志, 2006, 9(5): 388-391.
42. Mariette C, Balon JM, Piessen G,et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer, 2003, 97(7): 1616-1623.
43. Tachibana M, Kinugasa S, Yoshimura H,et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg, 2005, 189(1): 98-109.
44. Law S, Wong J. Two-field dissection is enough for esophageal cancer. Dis Esophagus, 2001, 14(2): 98-103.
45. Nakamura T, Ota M, Narumiya K,et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol, 2008, 15(9): 2451-2457.
46. Pennathur A, Zhang J, Chen H,et al. The “Best Operation” for Esophageal Cancer?. Ann Thorac Surg, 2010, 89(6): S2163-S2167.
47. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol, 2007, 8(6): 545-553.
48. Ando N, Iizuka T, Ide H,et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study——JCOG9204. J Clin Oncol, 2003, 21(24): 4592-4596.
49. Pouliquen X, Levard H, Hay JM,et al. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg, 1996, 223(2): 127-133.
50. Nagawa H, Seto Y, Kobori O,et al. An experience of treatment for patients with thoracic esophageal cancer invading adjacent organs. Jpn J Clin Oncol, 1997, 27(4): 248-250.
51. Armanios M, Xu R, Forastiere AA,et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase Ⅱ trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol, 2004, 22(22): 4495-4499.
52. Ténière P, Hay JM, Fingerhut A,et al. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet, 1991, 173(2): 123-130.
53. Zieren HU, Müller JM, Jacobi CA,et al. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg, 1995, 19(3): 444-449.
54. Fok M, Sham JS, Choy D,et al. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery, 1993, 113(2): 138-147.
55. Xiao ZF, Yang ZY, Liang J,et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg, 2003, 75(2): 331-336.
56. Malthaner RA, Wong RK, Rumble RB,et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med, 2004, 2(1): 35.
57. Almhanna K, Shridhar R, Meredith KL. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?. Cancer Control, 2013, 20(2): 89-96.
58. Bédard EL, Inculet RI, Malthaner RA,et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer, 2001, 91(12): 2423-2430.
59. Adelstein DJ, Rice TW, Rybicki LA,et al. Mature results from a phase Ⅱ trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol, 2009, 4(10): 1264-1269.
60. Chen JQ, Pan JJ, Liu J,et al. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2013, 86(4): 671-677.
61. Tachibana M, Yoshimura H, Kinugasa S,et al. Postoperative chemotherapyvs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol, 2003, 29(7): 580-587.
62. Ma DY, Tan BX, Liu M,et al. Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study. Radiat Oncol, 2014, 9(9): 28.
63. Zhang J, Peng F, Li N,et al. Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer. Radiat Oncol, 2012, 7(7): 93.
64. Bao Y, Liu S, Zhou Q,et al. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern. Radiat Oncol, 2013, 8(8): 241.
65. Walsh TN, Noonan N, Hollywood D,et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med, 1996, 335(7): 462-467.
66. Crosby TD, Brewster AE, Borley A,et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer, 2004, 90(1): 70-75.
67. Ohtsu A, Boku N, Muro K,et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol, 1999, 17(8): 2915-2921.
68. Ishikura S, Nihei K, Ohtsu A,et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol, 2003, 21(14): 2697-2702.
69. Hironaka S, Ohtsu A, Boku N,et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys, 2003, 57(2): 425-433.
70. Chiu PW, Chan AC, Leung SF,et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE) J Gastrointest Surg, 2005, 9(6): 794-802.
71. Besharat S, Jabbari A, Semnani S,et al. Inoperable esophageal cancer and outcome of palliative care. World J Gastroenterol, 2008, 14(23): 3725-3728.
72. Yano T, Muto M, Minashi K,et al. Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc, 2005, 62(1): 31-36.
73. Lightdale CJ, Heier SK, Marcon NE,et al. Photodynamic therapy with porfimer sodiumversus thermal ablation therapy with Nd: YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc, 1995, 42(6): 507-512.
74. Müller JM, Erasmi H, Stelzner M,et al. Surgical therapy for esophageal adenocarcinoma. J Gastrointest Surg, 2002, 6(4): 515.
75. Frenken M. Best palliation in esophageal cancer: surgery, stenting, radiation, or what?. Dis Esophagus, 2001, 14(2): 120-123.
76. Freeman RK, Ascioti AJ, Mahidhara RJ. Palliative therapy for patients with unresectable esophageal carcinoma. Surg Clin North Am, 2012, 92(5): 1337-1351.
77. Mohamed A, El-Rayes B, Khuri FR,et al. Targeted therapies in metastatic esophageal cancer: advances over the past decade. Crit Rev Oncol Hematol, 2014, 91(2): 186-196.
78. Hong TS, Wo JY, Kwak EL. Targeted therapies with chemoradiation in esophageal cancer: development and future directions. Semin Radiat Oncol, 2013, 23(1): 31-37.
79. Lin CC, Papadopoulos KP. Novel targeted therapies for advanced esophageal cancer. Dis Esophagus, 2007, 20(5): 365-371.
80. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist, 2005, 10(8): 590-601.
81. Tabernero J, Macarulla T, Ramos FJ,et al. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol, 2005, 16(11): 1740-1748.
82. Liberman M, Hanna N, Duranceau A,et al. Endobronchial ultrasonography added to endoscopic ultrasonography improves staging in esophageal cancer. Ann Thorac Surg, 2013, 96(1): 232-236; discussion 236.
83. van Vliet EP, Heijenbrok-Kal MH, Hunink MG,et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer, 2008, 98(3): 547-557.
84. Meyers BF, Downey RJ, Decker PA,et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg, 2007, 133(3): 738-745.
85. Luketich JD, Kassis ES, Shriver SP,et al. Detection of micrometastases in histologically negative lymph nodes in esophageal cancer. Ann Thorac Surg, 1998, 66(5): 1715-1718.
86. Prenzel KL, H?lscher AH, Drebber U,et al. Prognostic impact of nodal micrometastasis in early esophageal cancer. Eur J Surg Oncol, 2012, 38(4): 314-318.

West China Medical Journal

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content